Journal
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
Volume 3, Issue 2, Pages 103-108Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jgar.2015.03.007
Keywords
beta-Lapachone; Liposomes; Antimicrobial activity; Meticillin-resistant; Staphylococcus aureus; MRSA; Cryptococcus neoformans
Categories
Funding
- Brazilian National Research Council (CNPq) [484574/2011-6]
- Universidade Federal de Pernambuco (UFPE)
- CNPq
Ask authors/readers for more resources
The aim of this study was to determine whether encapsulation of beta-lapachone (beta-lap) into liposomes interferes with its in vitro antimicrobial activity against meticillin-resistant Staphylococcus aureus (MRSA) and Cryptococcus neoformans clinical strains. Liposomes (beta-lap:lipo or beta-lap:HP beta-CD-lipo) were prepared using the hydration of thin lipid film method followed by sonication. The in vitro antimicrobial activities of beta-lap-loaded liposomes against MRSA and C. neoformans were evaluated using the microdilution method according to the Clinical and Laboratory Standards Institute (CLSI). The liposomes presented a mean particle size ranging from 88.7 +/- 1.5 nm to 112.4 +/- 1.9 nm with a polydispersity index ranging from 0.255 to 0.340, zeta potential from 0.26 +/- 0.01 mV to +0.25 +/- 0.05 mV and drug encapsulation efficiency from 97.4 +/- 0.3% to 98.9 +/- 0.4%. beta-Lap and beta-lap:HP beta-CD had minimum inhibitory concentrations (MICs) ranging from 2 mg/L to 4 mg/L, whereas the MICs of beta-lap-lipo or beta-lap:HP beta-CD-lipo ranged from 4 mg/L to 16 mg/L for the MRSA strains tested. beta-Lap and beta-lap:HP beta-CD were able to inhibit fungal growth [MIC = 2-8 mg/L and minimum fungicidal concentration (MFC) = 4-8 mg/L]. However, beta-lap-lipo and beta-lap:HP beta-CD-lipo were more efficient, with MICs and MFCs of <4 mg/L. These findings suggest that the liposomal formulations tested do not interfere significantly with beta-lap antibacterial activity against MRSA and improve its antifungal properties against C. neoformans. (C) 2015 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available